Insmed (INSM)
(Delayed Data from NSDQ)
$74.50 USD
+0.07 (0.09%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $74.48 -0.02 (-0.03%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
INSM 74.50 +0.07(0.09%)
Will INSM be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for INSM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for INSM
Insmed (INSM) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Insmed (INSM) Stock Soars 118% on Upbeat Lung Disease Drug Data
INSM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Insmed (INSM) Beats on Q1 Earnings, Posts Upbeat Pipeline Updates
Insmed (INSM) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
Insmed (INSM) Reports Q1 Loss, Lags Revenue Estimates
Other News for INSM
Artisan Mid Cap Fund Q2 2024 Commentary
Russell rotation: YTD market capitalizations swelling for small-caps
Here's How Much $100 Invested In Insmed 10 Years Ago Would Be Worth Today
ClearBridge Small Cap Growth Strategy Q2 2024 Commentary
Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)